Skip to main content

Table 1 Anthropometric and clinical data of the study population

From: Metabolomic approach to profile functional and metabolic changes in heart failure

 

Group A (N = 9)

Group B (N = 9)

Group C (N = 15)

Age (years)

64.9 ± 8.3

66.1 ± 7.9

66.7 ± 9.9

M/F

7/2

8/2

10/5

Height (m)

1.63 ± 0.06

1.67 ± 0.51

1.67 ± 0.45

Weight (kg)

67.2 ± 12.4

74.0 ± 10.6

72.9 ±9.6

BMI (kg/m2)

25.2 ± 3.2

26.4 ± 3.9

26.04 ± 2.7

BSA (m2)

1.74 ± 0.17

1.85 ± 0.20

1.84 ± 0.26

Diabetes

1

1

1

NYHA class

 I

9

8

0

 II

0

1

2

 III

0

0

13*

 IV

0

0

0

Aetiology

 Ischaemic

4

7

 Valvular

1

1

 DCM

4

6

 Hypertensive

0

1

 Other

0

0

Drugs

 β-blockers

 

9

14

 ACE-inhibitors

6

9

 ARBs

3

6

 Diuretics

7

15

 Aldosterone antagonists

3

5

 Ca-antagonists

4

1

 Antiarrythmics

1

2

 Acetylsalicylic acid

6

10

 Antiplatelet agents

0

1

 Anticoagulants

1

2

 Statins

7

9

 Other hypolipidemic agents

0

3

 Insulin

1

1

 Oral antidiabetic agents

1

1

 Digoxin

1

1

 Nitroderivates

2

0

 Other antihypertensive drugs

1

0

  1. BMI body mass index, BSA body surface area, DCM dilated cardiomyopathy
  2. * p < 0.02 vs Group B